Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients With Liver Cirrhosis and Ascites: a Multicentre, Randomised Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event. By creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

⁃ Patients eligible for inclusion in this trial must meet all of the following criteria:

• Patients ≥ 18 years and \< 80 years

• Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features

• Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites

• INR ≤ 1.5

• Ability to understand the nature of the trial and the trial related procedures and to comply with them

Locations
Other Locations
Germany
University Medical Center Freiburg
RECRUITING
Freiburg Im Breisgau
Contact Information
Primary
Dominik Bettinger, MD
dominik.bettinger@uniklinik-freiburg.de
+4976127036870
Backup
Marco Janoschke, PhD
marco.janoschke@uniklinik-freiburg.de
+4976127077831
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2029-02-15
Participants
Target number of participants: 134
Treatments
Experimental: Transjugular intrahepatic portosystemic shunt (TIPS)
Patients will receive TIPS implantation if ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites occurs.
No_intervention: Standard medical treatment
Patients in this group will receive standard medical treatment according to the current EASL guidelines (salt restriction, diuretic treatment, carvedilol, large-volume paracentesis if necessary, albumin substitution if more than 5 litre of ascites is removed)
Sponsors
Collaborators: Jena University Hospital, University of Leipzig, Heinrich-Heine University, Duesseldorf, University Hospital Muenster, Johannes Gutenberg University Mainz, Hannover Medical School, University Hospital Lübeck, University Hospital, Bonn, University Hospital Munich (LMU), University Hospital, Aachen
Leads: University Hospital Freiburg

This content was sourced from clinicaltrials.gov